Biomedical progress in therapeutics has been hindered despite advances in basic science, a trend known as Eroom's Law. The Clinical Trial Abundance Project aims to enhance the efficiency and informativeness of clinical trials, arguing that learning from both successes and failures is crucial for developing new therapies, as exemplified by the evolution of CAR-T cell therapies.

CAR-T cell therapy, a groundbreaking immunotherapy successfully used to treat leukemia, has evolved since its initial approval, but challenges remain in treating solid tumors and managing treatment toxicity. New therapies, including radiopharmaceuticals and therapeutic cancer vaccines, are emerging and show promise in overcoming these challenges, with ongoing clinical trials aiming to improve cancer treatment outcomes.